Suet-Wan Choy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suet-Wan Choy has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- David Anthony Power
Kidney Laboratory, Institute for Breathing and Sleep, University of Melbourne, Heidelberg, Victoria, Australia
4 shared publications Natasha Cook
Department of Nephrology Austin Health Melbourne Victoria Australia
3 shared publications- Peter Francis Mount
Department of Nephrology (Kidney Laboratory), Austin Health, Melbourne, Victoria, Australia; Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia
3 shared publications Kathy Paizis
Austin Health
2 shared publications- Kathy Paizis
Department of Nephrology, Austin Health, Melbourne, Australia
2 shared publications Marina Katerelos
Austin Health
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0359105
Analysis of urinary kidney-specific cell-free DNA in preeclampsia
Aim: To assess the feasibility of a novel methodology for quantifying kidney-specific cell-free DNA (ks-cfDNA) and explore whether levels differed between individuals with preeclampsia (PE) and normotensive pregnant controls (NP). Background: Cell-free DNA (cfDNA) is released during cell death and circulates in bodily fluids, including urine. cfDNA quantities reflect the degree of organ injury. As PE is associated with hypertension and kidney injury, we hypothesised that urinary ks-cfDNA would be elevated in PE. Methods: In this single-centre prospective case-control study urine samples were collected from 20 women with PE and 20 NP controls. Digital PCR was used to quantify three kidney-specific epigenetic targets (ks-et): ks-et1 (pan-kidney marker), ks-et2 (renal proximal tubular epithelial cell (RPTEC) and podocyte marker) and ks-et3 (RPTEC marker). The beta-actin gene (ACTB) represented total cfDNA (t-cfDNA). Results: ks-et2 and ks-et3 were higher in the PE group. Median ks-et2 was 231 copies/mL (IQR 65–383) versus 62 copies/mL (IQR 29–215) in NP controls ( P = 0.028). Median ks-et3 was 81 copies/mL (IQR 28–199) in PE versus 20 copies/mL (IQR 9–81) for NP participants ( P = 0.047). ks-et1 and t-cfDNA showed non-significant increases in PE. Fractional ks-et quantities normalised to t-cfDNA did not differ between groups. Urinary creatinine levels were higher in the PE group (10.9 mmol/L (IQR 4.1–15.3) versus 3.9 mmol/L (IQR 2.3–5.6), P = 0.005). Urine creatinine demonstrated the highest AUC (0.76, 95% CI 0.59–0.92). Conclusion: This exploratory study found that quantification of urinary ks-cfDNA was feasible and that absolute quantities of ks-cfDNA markers ks-et2 and ks-et3 were elevated in PE. Consistent with previous studies, urinary creatinine was a good predictor of PE and outperformed ks-cfDNA in discriminating between preeclamptic and normotensive pregnancies. Further studies are needed to determine the clinical utility and predictive ability of ks-cfDNA in PE.
- 29 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0359105
Open AccessAnalysis of urinary kidney-specific cell-free DNA in preeclampsia
Aim: To assess the feasibility of a novel methodology for quantifying kidney-specific cell-free DNA (ks-cfDNA) and explore whether levels differed between individuals with preeclampsia (PE) and normotensive pregnant controls (NP). Background: Cell-free DNA (cfDNA) is released during cell death and circulates in bodily fluids, including urine. cfDNA quantities reflect the degree of organ injury. As PE is associated with hypertension and kidney injury, we hypothesised that urinary ks-cfDNA would be elevated in PE. Methods: In this single-centre prospective case-control study urine samples were collected from 20 women with PE and 20 NP controls. Digital PCR was used to quantify three kidney-specific epigenetic targets (ks-et): ks-et1 (pan-kidney marker), ks-et2 (renal proximal tubular epithelial cell (RPTEC) and podocyte marker) and ks-et3 (RPTEC marker). The beta-actin gene (ACTB) represented total cfDNA (t-cfDNA). Results: ks-et2 and ks-et3 were higher in the PE group. Median ks-et2 was 231 copies/mL (IQR 65–383) versus 62 copies/mL (IQR 29–215) in NP controls ( P = 0.028). Median ks-et3 was 81 copies/mL (IQR 28–199) in PE versus 20 copies/mL (IQR 9–81) for NP participants ( P = 0.047). ks-et1 and t-cfDNA showed non-significant increases in PE. Fractional ks-et quantities normalised to t-cfDNA did not differ between groups. Urinary creatinine levels were higher in the PE group (10.9 mmol/L (IQR 4.1–15.3) versus 3.9 mmol/L (IQR 2.3–5.6), P = 0.005). Urine creatinine demonstrated the highest AUC (0.76, 95% CI 0.59–0.92). Conclusion: This exploratory study found that quantification of urinary ks-cfDNA was feasible and that absolute quantities of ks-cfDNA markers ks-et2 and ks-et3 were elevated in PE. Consistent with previous studies, urinary creatinine was a good predictor of PE and outperformed ks-cfDNA in discriminating between preeclamptic and normotensive pregnancies. Further studies are needed to determine the clinical utility and predictive ability of ks-cfDNA in PE.
- Open Access
- 2 July 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 62 (4) , 400-418
Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
Background: The prevalence of chronic kidney disease (CKD) in patients with inflammatory bowel disease (IBD) is increasing. The pharmacokinetic profiles of IBD medications in patients with advanced‐stage CKD are not well studied.Aim: To provide evidence‐based guidance on the use of medical therapies in patients with IBD and CKD.Methods: We conducted a narrative review of literature up to 31 March 2025 on studies of therapies currently used for the treatment of IBD in the setting of CKD, with a focus on advanced kidney disease and use in renal replacement therapy.Results: Mesalazine can cause acute interstitial nephritis. Calcineurin inhibitors have been associated with nephrotoxicity. Methotrexate is contraindicated in advanced renal disease, including while on renal replacement therapy, due to higher risks of toxicity and myelosuppression. Dose adjustment of thiopurines should be considered in advanced renal disease due to metabolite accumulation. Monoclonal antibodies, including anti‐tumour necrosis factor therapy, anti‐integrin therapy and anti‐interleukin 12/23 therapies, appear to be safe in renal insufficiency, including haemodialysis. There is limited data available for small molecule therapies; drug metabolism profiles suggest they are safe in CKD, although, for Janus kinase (JAK) inhibitors, including tofacitinib and upadacitinib, dose reduction should be considered in advanced renal disease.Conclusion: Most therapies used in IBD, particularly biologic therapies, appear safe and effective when used in patients with CKD, including those on renal replacement therapy. Caution should be considered when using conventional therapies and JAK inhibitors.
- 2 July 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 62 (4) , 400-418
Open AccessPrescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
Background: The prevalence of chronic kidney disease (CKD) in patients with inflammatory bowel disease (IBD) is increasing. The pharmacokinetic profiles of IBD medications in patients with advanced‐stage CKD are not well studied.Aim: To provide evidence‐based guidance on the use of medical therapies in patients with IBD and CKD.Methods: We conducted a narrative review of literature up to 31 March 2025 on studies of therapies currently used for the treatment of IBD in the setting of CKD, with a focus on advanced kidney disease and use in renal replacement therapy.Results: Mesalazine can cause acute interstitial nephritis. Calcineurin inhibitors have been associated with nephrotoxicity. Methotrexate is contraindicated in advanced renal disease, including while on renal replacement therapy, due to higher risks of toxicity and myelosuppression. Dose adjustment of thiopurines should be considered in advanced renal disease due to metabolite accumulation. Monoclonal antibodies, including anti‐tumour necrosis factor therapy, anti‐integrin therapy and anti‐interleukin 12/23 therapies, appear to be safe in renal insufficiency, including haemodialysis. There is limited data available for small molecule therapies; drug metabolism profiles suggest they are safe in CKD, although, for Janus kinase (JAK) inhibitors, including tofacitinib and upadacitinib, dose reduction should be considered in advanced renal disease.Conclusion: Most therapies used in IBD, particularly biologic therapies, appear safe and effective when used in patients with CKD, including those on renal replacement therapy. Caution should be considered when using conventional therapies and JAK inhibitors.
- 19 January 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (10) , 1691-1699
Dialysis and driving: an anonymous survey of patients receiving dialysis for end‐stage kidney disease
Background: Driving is a complex task requiring multiple cognitive domains and the musculoskeletal system. Cognitive dysfunction is associated with driving impairment. Dialysis patients are known to have a high prevalence of cognitive impairment and other comorbidities, and may be at risk of driving impairment. No Australian guidelines address driving safety in dialysis patients.Aims: To estimate the proportion of dialysis patients who were driving and those at risk of driving impairment, and to investigate the agreement between objective and subjective markers of risk.Methods: This single‐centre study involved dialysis patients voluntarily completing two questionnaires relating to risk of driving impairment; the first questionnaire focussed on objective markers, and the second questionnaire focussed on subjective markers. Risk of driving impairment was established using pre‐determined criteria, and the agreement between objective and subjective markers was estimated using Cohen kappa.Results: A total of 44.8% (99/221) of patients participated; 76.8% (76/99) of participants were driving, and 76.3% (58/76) of drivers were at risk of driving impairment. Factors associated with at‐risk driving included post dialysis dizziness, leg weakness or numbness, falling asleep while driving and hypoglycaemia. Sixteen patients reported collisions since commencing dialysis. The questionnaires displayed slight agreement (Cohen kappa = 0.20) between objective and subjective markers.Conclusions: Dialysis patients are at risk of driving impairment based on self‐reported questionnaire responses. Discrepancies between patients' perceptions and objective markers were apparent. Further research into appropriate risk assessments, as well as development of guidelines to aid in determining driving safety in dialysis patients, is needed.
- 19 January 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (10) , 1691-1699
Dialysis and driving: an anonymous survey of patients receiving dialysis for end‐stage kidney disease
Background: Driving is a complex task requiring multiple cognitive domains and the musculoskeletal system. Cognitive dysfunction is associated with driving impairment. Dialysis patients are known to have a high prevalence of cognitive impairment and other comorbidities, and may be at risk of driving impairment. No Australian guidelines address driving safety in dialysis patients.Aims: To estimate the proportion of dialysis patients who were driving and those at risk of driving impairment, and to investigate the agreement between objective and subjective markers of risk.Methods: This single‐centre study involved dialysis patients voluntarily completing two questionnaires relating to risk of driving impairment; the first questionnaire focussed on objective markers, and the second questionnaire focussed on subjective markers. Risk of driving impairment was established using pre‐determined criteria, and the agreement between objective and subjective markers was estimated using Cohen kappa.Results: A total of 44.8% (99/221) of patients participated; 76.8% (76/99) of participants were driving, and 76.3% (58/76) of drivers were at risk of driving impairment. Factors associated with at‐risk driving included post dialysis dizziness, leg weakness or numbness, falling asleep while driving and hypoglycaemia. Sixteen patients reported collisions since commencing dialysis. The questionnaires displayed slight agreement (Cohen kappa = 0.20) between objective and subjective markers.Conclusions: Dialysis patients are at risk of driving impairment based on self‐reported questionnaire responses. Discrepancies between patients' perceptions and objective markers were apparent. Further research into appropriate risk assessments, as well as development of guidelines to aid in determining driving safety in dialysis patients, is needed.
- Open Access
- 28 February 2019
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 17 (1) , 60
Increased expression and phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoforms in urinary exosomes in pre-eclampsia
Glycolysis is altered in various kidney diseases, but little is known about glycolysis in pre-eclampsia, a multi-system disorder with major pathological effects on the kidney. Urinary exosomes provide a non-invasive alternative for studying changes in kidney metabolism. This study aims to characterise the expression and phosphorylation of isozymes of the key glycolytic regulatory protein, 6-phosphofructokinase-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2), in urinary exosomes of subjects with pre-eclampsia (PE), compared to normotensive non-pregnant (NC) and normotensive pregnant (NP) controls. A cross-sectional study of NC (n = 19), NP (n = 23) and PE (n = 29) subjects was performed. Exosomes were isolated from urine samples by differential ultracentrifugation, and then analyzed by Western blot and densitometry for expression of PFK-2/FBPase-2 isozymes (PFKFB2, PFKFB3 and PFKFB4) and phosphorylation of PFKFB2 at residues Ser483 and Ser466 and PFKFB3 at Ser461. PFKFB2 expression was increased 4.7-fold in PE compared to NP (p < 0.001). PFKFB2 phosphorylation at Ser483 was increased 2.6-fold in PE compared to NP (p = 0.002). Expression of phosphorylated PFKFB2/PFKFB3 at Ser466/Ser461 was increased in PE, being present in 77.4% (95% CI 59.9–88.9%) of PE and 8.3% (95% CI 1.2–27.0%) of NP samples (p < 0.001). PFKFB3 was more commonly expressed in PE, detected in 90.3% (95% CI 74.3–97.4%) of PE and 8.3% (95% CI 1.2–27.0%) of NP samples (p < 0.001). PFKFB4 had a 7.2-fold increase in expression in PE compared to NP (p < 0.001). No significant differences between NP and NC groups were observed. Regulatory proteins that increase glycolysis are increased in the urinary exosomes of subjects with pre-eclampsia, suggesting that renal glycolysis may be increased in this condition.
- 28 February 2019
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 17 (1) , 60
Open AccessIncreased expression and phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoforms in urinary exosomes in pre-eclampsia
Glycolysis is altered in various kidney diseases, but little is known about glycolysis in pre-eclampsia, a multi-system disorder with major pathological effects on the kidney. Urinary exosomes provide a non-invasive alternative for studying changes in kidney metabolism. This study aims to characterise the expression and phosphorylation of isozymes of the key glycolytic regulatory protein, 6-phosphofructokinase-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2), in urinary exosomes of subjects with pre-eclampsia (PE), compared to normotensive non-pregnant (NC) and normotensive pregnant (NP) controls. A cross-sectional study of NC (n = 19), NP (n = 23) and PE (n = 29) subjects was performed. Exosomes were isolated from urine samples by differential ultracentrifugation, and then analyzed by Western blot and densitometry for expression of PFK-2/FBPase-2 isozymes (PFKFB2, PFKFB3 and PFKFB4) and phosphorylation of PFKFB2 at residues Ser483 and Ser466 and PFKFB3 at Ser461. PFKFB2 expression was increased 4.7-fold in PE compared to NP (p < 0.001). PFKFB2 phosphorylation at Ser483 was increased 2.6-fold in PE compared to NP (p = 0.002). Expression of phosphorylated PFKFB2/PFKFB3 at Ser466/Ser461 was increased in PE, being present in 77.4% (95% CI 59.9–88.9%) of PE and 8.3% (95% CI 1.2–27.0%) of NP samples (p < 0.001). PFKFB3 was more commonly expressed in PE, detected in 90.3% (95% CI 74.3–97.4%) of PE and 8.3% (95% CI 1.2–27.0%) of NP samples (p < 0.001). PFKFB4 had a 7.2-fold increase in expression in PE compared to NP (p < 0.001). No significant differences between NP and NC groups were observed. Regulatory proteins that increase glycolysis are increased in the urinary exosomes of subjects with pre-eclampsia, suggesting that renal glycolysis may be increased in this condition.
- Open Access
- 24 September 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (9) , e0204514
Pre-eclampsia is associated with altered expression of the renal sodium transporters NKCC2, NCC and ENaC in urinary extracellular vesicles
Pre-eclampsia is a hypertensive disorder of pregnancy characterised by hypertension and sodium retention by the kidneys. To identify changes in sodium uptake proteins in the tubules of the distal nephron, we studied their expression in urinary extracellular vesicles or exosomes (uEVs). Urine was collected from women with pre-eclampsia or during normal pregnancy, and from healthy non-pregnant controls. uEVs were isolated by centrifugation and analyzed by Western blot. Expression, proteolytic cleavage and phosphorylation was determined by densitometric analysis normalized to the exosome marker CD9. Results showed a significant increase in phosphorylation of the activating S130 site in NKCC2, the drug target for frusemide, in women with pre-eclampsia compared with normal pregnant women. Phosphorylation of the activating sites T101/105 in NKCC2 was similar but the activating T60 site in NCC, the drug target for thiazide diuretics, showed significantly less phosphorylation in pre-eclampsia compared with normal pregnancy. Expression of the larger forms of the α subunit of ENaC, the drug target for amiloride, was significantly greater in pre-eclampsia, with more fragmentation of theγ subunit. The differences observed are predicted to increase the activity of NKCC2 and ENaC while reducing that of NCC. This will increase sodium reabsorption, and so contribute to hypertension in pre-eclampsia.
- 24 September 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (9) , e0204514
Open AccessPre-eclampsia is associated with altered expression of the renal sodium transporters NKCC2, NCC and ENaC in urinary extracellular vesicles
Pre-eclampsia is a hypertensive disorder of pregnancy characterised by hypertension and sodium retention by the kidneys. To identify changes in sodium uptake proteins in the tubules of the distal nephron, we studied their expression in urinary extracellular vesicles or exosomes (uEVs). Urine was collected from women with pre-eclampsia or during normal pregnancy, and from healthy non-pregnant controls. uEVs were isolated by centrifugation and analyzed by Western blot. Expression, proteolytic cleavage and phosphorylation was determined by densitometric analysis normalized to the exosome marker CD9. Results showed a significant increase in phosphorylation of the activating S130 site in NKCC2, the drug target for frusemide, in women with pre-eclampsia compared with normal pregnant women. Phosphorylation of the activating sites T101/105 in NKCC2 was similar but the activating T60 site in NCC, the drug target for thiazide diuretics, showed significantly less phosphorylation in pre-eclampsia compared with normal pregnancy. Expression of the larger forms of the α subunit of ENaC, the drug target for amiloride, was significantly greater in pre-eclampsia, with more fragmentation of theγ subunit. The differences observed are predicted to increase the activity of NKCC2 and ENaC while reducing that of NCC. This will increase sodium reabsorption, and so contribute to hypertension in pre-eclampsia.
- 20 May 2017
- Published by Wiley in Nephrology
- Vol. 23 (7) , 616-624
Use of a new end‐stage kidney disease risk calculator in the Kidney Disease Improving Global Outcomes guideline to evaluate the impact of different living kidney donor candidate assessments
Aim: The Kidney Disease Improving Global Outcomes (KDIGO) guideline recommends the incorporation of a new risk calculator that quantifies the end‐stage kidney disease (ESKD) risk based on a composite profile of risk factors in living kidney donor candidates (LKDC). We compared the ESKD risk estimates in previously declined versus accepted LKDC to evaluate the predictive capacity and potential impact of this tool.Methods: Baseline 15 year and lifetime ESKD risk estimates without donation were calculated using the risk calculator for LKDC assessed from two centres between 2007 and 2015. LKDC suitability based on the proposed KDIGO and the existing Caring for Australasians with Renal Impairment national guidelines was compared.Results: Median 15 year ESKD risk was 0.14% (IQR 0.09–0.31%) in declined LKDC (n=59) versus 0.10% (0.07–0.14%) in accepted LKDC (n=89) (Pversus 0.35% (0.22–0.56%), respectively; however, declined LKDC had a higher 98% risk percentile value (8.19% vs 1.02%) and were more likely to exceed a 1% ESKD risk threshold (15% vs 1%; P1%. This risk calculator appears to complement but not replace clinical evaluation.
- 20 May 2017
- Published by Wiley in Nephrology
- Vol. 23 (7) , 616-624
Use of a new end‐stage kidney disease risk calculator in the Kidney Disease Improving Global Outcomes guideline to evaluate the impact of different living kidney donor candidate assessments
Aim: The Kidney Disease Improving Global Outcomes (KDIGO) guideline recommends the incorporation of a new risk calculator that quantifies the end‐stage kidney disease (ESKD) risk based on a composite profile of risk factors in living kidney donor candidates (LKDC). We compared the ESKD risk estimates in previously declined versus accepted LKDC to evaluate the predictive capacity and potential impact of this tool.Methods: Baseline 15 year and lifetime ESKD risk estimates without donation were calculated using the risk calculator for LKDC assessed from two centres between 2007 and 2015. LKDC suitability based on the proposed KDIGO and the existing Caring for Australasians with Renal Impairment national guidelines was compared.Results: Median 15 year ESKD risk was 0.14% (IQR 0.09–0.31%) in declined LKDC (n=59) versus 0.10% (0.07–0.14%) in accepted LKDC (n=89) (Pversus 0.35% (0.22–0.56%), respectively; however, declined LKDC had a higher 98% risk percentile value (8.19% vs 1.02%) and were more likely to exceed a 1% ESKD risk threshold (15% vs 1%; P1%. This risk calculator appears to complement but not replace clinical evaluation.
- Open Access
- 11 December 2015
- Published by MDPI AG in Metabolites
- Vol. 5 (4) , 720-732
Obesity-Related Chronic Kidney Disease—The Role of Lipid Metabolism
Obesity is an independent risk factor for chronic kidney disease (CKD). The mechanisms linking obesity and CKD include systemic changes such as high blood pressure and hyperglycemia, and intrarenal effects relating to lipid accumulation. Normal lipid metabolism is integral to renal physiology and disturbances of renal lipid and energy metabolism are increasingly being linked with kidney disease. AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) are important regulators of fatty acid oxidation, which is frequently abnormal in the kidney with CKD. A high fat diet reduces renal AMPK activity, thereby contributing to reduced fatty acid oxidation and energy imbalance, and treatments to activate AMPK are beneficial in animal models of obesity-related CKD. Studies have found that the specific cell types affected by excessive lipid accumulation are proximal tubular cells, podocytes, and mesangial cells. Targeting disturbances of renal energy metabolism is a promising approach to addressing the current epidemic of obesity-related kidney disease.
- 11 December 2015
- Published by MDPI AG in Metabolites
- Vol. 5 (4) , 720-732
Open AccessObesity-Related Chronic Kidney Disease—The Role of Lipid Metabolism
Obesity is an independent risk factor for chronic kidney disease (CKD). The mechanisms linking obesity and CKD include systemic changes such as high blood pressure and hyperglycemia, and intrarenal effects relating to lipid accumulation. Normal lipid metabolism is integral to renal physiology and disturbances of renal lipid and energy metabolism are increasingly being linked with kidney disease. AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) are important regulators of fatty acid oxidation, which is frequently abnormal in the kidney with CKD. A high fat diet reduces renal AMPK activity, thereby contributing to reduced fatty acid oxidation and energy imbalance, and treatments to activate AMPK are beneficial in animal models of obesity-related CKD. Studies have found that the specific cell types affected by excessive lipid accumulation are proximal tubular cells, podocytes, and mesangial cells. Targeting disturbances of renal energy metabolism is a promising approach to addressing the current epidemic of obesity-related kidney disease.